World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

What makes us special?

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

What makes us special?

Richmond Pharmacology delivers clinical excellence from design to delivery. Our long-term working relationships with our international client-base has led to the completion of over 500 Early Phase Studies.

We provide a personal service. Our founders are influential clinical research experts and lead each clinical trial. Our team of senior drug development experts are also on hand to ensure the quality, integrity, and accuracy of your study. We are reputed for our customer-centric project management, our flexible approach, and the superior quality of the studies. As a sponsor, you will have high-level engagement and meaningful peer to peer conversations.

Accredited by the MHRA, we guarantee that our trials adhere to the highest clinical, ethical and safety standards and our processes are auditable.

Our efficient and adaptive approach leads to faster development times, accelerating the time to market from first in human trials to proof of concept in under nine months. Adding value by integrating ethnic comparison elements and intensive cardiac assessments.


The clinical unit is in the heart of London with easy access to mainline train stations and airports, making it the ideal location to attract research volunteers.

Richmond Pharmacology’s volunteer database exceeds 250,000 individuals from a broad demographic spectrum and a wide variety of patient panels across rare to more common diseases. The database grows by 1000 to 2000 volunteers each month with a typical 70/30 split between healthy volunteers and patients.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 3, 2021
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Read more